S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
NASDAQ:AVDL

Avadel Pharmaceuticals - AVDL Price Target & Analyst Ratings

$7.38
-0.09 (-1.20%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.31
$7.61
50-Day Range
$6.41
$10.00
52-Week Range
$1.05
$10.02
Volume
134,105 shs
Average Volume
380,456 shs
Market Capitalization
$455.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.71

Avadel Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$10.71
45.18% Upside
High Prediction$13.00
Average Prediction$10.71
Low Prediction$5.00
TypeCurrent
1/28/22 to 1/28/23
1 Month Ago
12/29/21 to 12/29/22
3 Months Ago
10/30/21 to 10/30/22
1 Year Ago
1/28/21 to 1/28/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.71$10.71$10.29$16.00
Predicted Upside45.18% Upside103.75% Upside103.03% Upside120.23% Upside
Get Avadel Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.


AVDL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AVDL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Avadel Pharmaceuticals Stock vs. The Competition

TypeAvadel PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.64
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside45.18% Upside1,055.91% Upside9.96% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/30/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$6.50 ➝ $11.00+40.31%
11/21/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ami Fadia
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$8.00 ➝ $9.00+12.08%
8/11/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$6.00 ➝ $12.00+68.07%
7/28/2022Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$15.50 ➝ $12.00+169.66%
7/19/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$2.00 ➝ $5.00+1.21%
7/1/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Oren Livnat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$13.00+437.19%
5/27/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$13.00+439.42%
11/9/2020Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Sherman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/11/2020Ci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$22.00+180.25%
5/4/2020Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Amsellem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight$14.00 ➝ $18.00+95.65%
(Data available from 1/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












AVDL Price Target - Frequently Asked Questions

What is Avadel Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Avadel Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 5 buy ratings for AVDL. The average twelve-month price prediction for Avadel Pharmaceuticals is $10.71 with a high price target of $13.00 and a low price target of $5.00. Learn more on AVDL's analyst rating history.

Do Wall Street analysts like Avadel Pharmaceuticals more than its competitors?

Analysts like Avadel Pharmaceuticals more than other Medical companies. The consensus rating for Avadel Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how AVDL compares to other companies.

Is Avadel Pharmaceuticals being upgraded by Wall Street analysts?

Over the previous 90 days, Avadel Pharmaceuticals's stock had 1 upgrade by analysts.

Does Avadel Pharmaceuticals's stock price have much upside?

According to analysts, Avadel Pharmaceuticals's stock has a predicted upside of 103.75% based on their 12-month price targets.

What analysts cover Avadel Pharmaceuticals?

Avadel Pharmaceuticals has been rated by Jefferies Financial Group, and Needham & Company LLC in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:AVDL) was last updated on 1/28/2023 by MarketBeat.com Staff